ストックスクリーナーアプリを入手
2.74
15.17%
-0.49
プレマーケット:
2.83
0.09
+3.28%
前日終値:
$3.23
開ける：
$3.28
24時間の取引高:
275.63K
Relative Volume:
1.97
時価総額：
$81.55M
収益：
-
当期純損益:
$-13.08M
株価収益率:
-6.2047
EPS:
-0.4416
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-36.87%
1か月 パフォーマンス:
-31.50%
6か月 パフォーマンス:
-53.56%
1年 パフォーマンス:
-49.82%
1日の値動き範囲:
$2.73
$3.49
1週間の範囲:
$2.73
$4.55
52週間の値動き範囲:
$2.73
$9.39
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
TELO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
2.74 | 81.55M | 0 | -13.08M | 0 | -0.4416 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-21 | 開始されました | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc (TELO) 最新ニュース
Charles Schwab Investment Management Inc. Boosts Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
TELO stock touches 52-week low at $3.1 amid market challenges By Investing.com - Investing.com South Africa
TELO stock touches 52-week low at $3.1 amid market challenges - Investing.com India
Virtu Financial LLC Acquires Shares of 14,959 Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Bank of New York Mellon Corp Increases Stock Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Analyzing Telomir Pharmaceuticals (TELO) & The Competition - Defense World
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells - Bluefield Daily Telegraph
Telomir Pharmaceuticals announces anti-cancer effects in prostate cancer animal model - MSN
SWK Holdings Announces Monetization of Royalty Portfolio - Waco Tribune-Herald
Telomir-1 shows promise in cancer and chemotherapy study By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals Says Telomir-1 Reduces Tumor Size in Prostate Cancer Animal Model - MarketScreener
Telomir-1 shows promise in cancer and chemotherapy study - Investing.com
Telomir Pharmaceuticals reports breakthrough in prostate cancer treatment By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals reports breakthrough in prostate cancer treatment - Investing.com India
Breakthrough: New Cancer Drug Cuts Prostate Tumors by Half While Reducing Chemo Toxicity - StockTitan
Telomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study Shows - Benzinga
Rhumbline Advisers Boosts Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest Up 34.4% in February - Defense World
Telomir-1 shows promise in reversing cell aging By Investing.com - Investing.com South Africa
Telomir-1 shows promise in reversing cell aging - Investing.com India
Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines - Eagle-Tribune
Could This Anti-Aging Compound Revolutionize Treatment for Alzheimer's and Macular Degeneration? - StockTitan
Telomir Pharmaceuticals announces Telomir-1 reverses calcium dysregulation in multiple human cell lines - MSN
Telomir Pharmaceuticals reports key preclinical success By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals reports key preclinical success - Investing.com India
Telomir Pharmaceuticals achieves breakthrough in silver ion stabilization - MSN
Telomir Pharmaceuticals (NASDAQ:TELO) Research Coverage Started at Rodman & Renshaw - Defense World
Telomir-1 exhibited strong ROS reduction properties, hold potential for AMD treatment - Ophthalmology Times
Telomir reports stabilization of silver forms for medical use By Investing.com - Investing.com Nigeria
Telomir Pharmaceuticals Says Telomir-1 Compound Stabilizes Silver for Advanced Medical Applications - Marketscreener.com
Telomir reports stabilization of silver forms for medical use - Investing.com
Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market - Weatherford Democrat
Telomir Pharmaceuticals announces silver ion breakthrough - Investing.com
Telomir Pharmaceuticals Seeks To Tap Multi-Billion-Dollar Market With Breakthrough In Silver Ion Stabilization For Antibacterial Treatment, Tissue Regeneration - Benzinga
TELO Again Announces Breakthrough Results - MSN
Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD) - Milton Daily Standard
What is Zacks Small Cap's Estimate for TELO Q1 Earnings? - MarketBeat
Telomir Pharmaceuticals (NASDAQ:TELO) Announces Earnings Results, Misses Estimates By $0.05 EPS - MarketBeat
What is Zacks Small Cap’s Estimate for TELO Q1 Earnings? - Defense World
Telomir Pharmaceuticals Inc. (TELO) reports earnings - Quartz
TELO Treatment Amazes in Preclinical Trial - MSN
Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecasts? - Barchart
Telomir Pharmaceuticals Announces Major Breakthrough in Reversing Oxidative Stress, Unlocking Potential for Treating Age-Related Diseases and Viruses Like Bird Flu - Barchart
Thrombotic Thrombocytopenic Purpura Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Global Blood Therapeutics, Sanofi, Carelon Research, Archemix Corp., Eisai Inc - Barchart
Mucopolysaccharidosis Type III Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Takeda Pharma, BioMarin Pharma, Ultragenyx Pharma, Sarepta - Barchart
Telomir Pharmaceuticals Inc (TELO) 財務データ
収益
当期純利益
現金流量
EPS
3.89%
0.13%
大文字化:
|
ボリューム (24 時間):